Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M

Estrella Immunopharma, Inc.

Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.
Non-compliance period identified as June 13, 2025 to July 31, 2025.
Company has 180 days, until Jan 28, 2026, to regain compliance with MVLS of $35M+ for 10 consecutive business days.
Also noted non-compliance with alternative listing rules 5550(b)(1) and 5550(b)(3).
No immediate effect on listing; Company will monitor and consider options but cannot assure regaining compliance.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.